Compare DFIN & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFIN | DBVT |
|---|---|---|
| Founded | 1983 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2017 | 2014 |
| Metric | DFIN | DBVT |
|---|---|---|
| Price | $46.93 | $20.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $61.50 | $31.75 |
| AVG Volume (30 Days) | 227.2K | ★ 248.3K |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $963,000,000.00 | $4,151,000.00 |
| Revenue This Year | $4.98 | $65.50 |
| Revenue Next Year | $3.87 | $47.02 |
| P/E Ratio | $40.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $37.07 | $5.30 |
| 52 Week High | $66.25 | $26.19 |
| Indicator | DFIN | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 45.85 | 46.03 |
| Support Level | $44.46 | $19.83 |
| Resistance Level | $48.65 | $24.47 |
| Average True Range (ATR) | 1.74 | 1.25 |
| MACD | -0.21 | -0.12 |
| Stochastic Oscillator | 33.56 | 26.10 |
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.